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4. HPV vaccination is expected to decrease the CIN3+ and cancer incidence substantially. I question whether we still need to use the same stringent criteria that we use for unvacinated cohorts with regard to extension of the interval, that is, control of CIN3+ rate. The optimal screening interval should provide optimal balance between screening-related harms and gains. In vaccinated cohorts, the harms will be large compared to the gains so safety is maybe not as important as in unvaccinated cohorts.
In sum, I think that a cohort study is also able to answer most of the questions that have been raised in the protocol, in particular because an extension of the interval in the intervention arm to 6 years has not been accepted by the authorities. Nonetheless, it seems still worth conductin the proposed study.
A minor point: l196. If non-inferiority is disproved, analysis for superiority will be carried out.. Disproved => proved.
cumulative risk of CIN3+ in baseline screen negative women after an estimated six year 172 interval of HPV-screening compared with two three year intervals of cytology-screening.
REVIEWER
Marion Saville Victorian Cytology Service Ltd Australia REVIEW RETURNED 06-Dec-2017
GENERAL COMMENTS
Firstly this is not an intervention study (I suppose this is why the ethics committee said it was a 'methods study'). The only intervention is screening as currently practiced and as such it does not differ between the study arms. Therefore it is unclear why randomisation is necessary. The authors state that the intervention is the HPV test performed in addition to cytology in the HPV arm (page 12). But, as can be seen in the flow diagram of the study arms, the HPV test does not influence management in any way i.e. being HPV positive is not used as a marker of elevated risk influencing subsequent follow up or management. Therefore this is not HPV screening and will not provide information about whether such screening is safe or effective in HPV vaccinated women. The most it could do is possibly provide information about whether cytologists detect cytological abnormalities better when they know that the woman is HPV positive given HPV status is unblinded.
The study is effectively an HPV prevalence survey of a cohort offered vaccination. It is not clear how the analysis will be conducted to establish non-inferiority given that no actual HPV primary screening is occurring. If diagnosed lesions are the outcome, there should be no difference between the arms as the screening is the same in each. If post-hoc censoring occurs for lesions diagnosed in HPV negative/ cytology positive women (these outcomes removed in HPV arm), then cytology alone will appear favourable.
What is not clear is how a theoretical 6 year HPV screening vs three year cytology comparison can be accurately constructed from this study. If all three year screening round outcomes in the HPV arm are treated as never occurring, then is it assumed that those lesions would have instead been detected in addition to the ones that actually were in the 6 year screening round? Are they upstaged? Would some of them have spontaneously regressed anyway? Would HPV screening have to be modelled from the data, assuming that those who were HPV positive, cytology negative were treated as screen positive rather than not acted upon as is the case in the study? The problem is this would not really be possible given that the positive predictive value of a positive HPV test for underlying clinically important high grade disease is not clearly established in 23 year olds. The trial data shows that HPV screening allows for earlier detection of clinically important lesions that can thus be treated earlier than cytology screening, which prevents subsequent cancer development more effectively. But these studies have not been done in very young vaccinated women. So it is very unclear how the study can add useful data to this question because the actual HPV screening outcomes in vaccinated young women are not being determined by the study -only cytology outcomes.
VERSION 1 -AUTHOR RESPONSE
Editors comments:
-Please revise the title of your manuscript to include the study setting.
ANSWER: The title has been changed to: "Protocol of a Danish randomized method study on cervical screening in women offered HPV-vaccination as girls (Trial23)".
-Please include a statement in your 'Ethics' section to indicate whether your study has been approved by Danish data protection agency.
ANSWER: The statement on approval from the Danish Data Protection Agency has been moved from "Data sources" to "Ethics and dissemination". It reads: "Handling and storage of data were approved by the Danish Data Inspective Agency (SUND-2016-22 Trial23 is an interesting study that will provide interesting data. However, a few important aspects of the study are unclear to me.
ANSWER: Thank you for the positive comment.
1. Is HPV status known when performing cytology reading in the HPV-arm? The HPV status should be known, otherwise the intervention arm cannot be interpreted as an HPV arm with cytology triage.
ANSWER: This is a limitation in the study, if one assumes that the cyto-technicians' interpretation of the cytology would differ, if they knew the outcome of the HPV-test beforehand. The study is conducted in five pathology departments with varying procedures. For logistic reasons, the study had to follow the routine procedures of the respective laboratories. The following paragraph has been added under 'limitations': "In primary HPV screening with cytology triage, the HPV status is known before the cytology. However, our study is embedded in the routine procedure in five pathology laboratories with primary cytology screening involving many laboratory technicians and pathologists. In some laboratories, the HPV-status is known before the cytology reading, in other laboratories cytology is read prior to the HPV-testing. This is a limitation of our study."
2. Only conization is mentioned as treatment option. I think LLETZ should be added.
ANSWER: The conizations are LLETZs. We have changed the wording and now used LLETZ instead of conization.
3. The primary end-point is slightly problematic because you compare different subgroups defined after randomization. This seems more like a secondary endpoint.
ANSWER: We see the point. The text now reads for Primary outcome: "How many cases of CIN3+ seen over two rounds of HPV-screening with cytology triage with a 6 year interval, including follow-up after 3 years of women HPV-positive and cytology normal at baseline, would have been seen over three rounds of cytology screening with a 3 year interval." And for Secondary outcome: "Number of colposcopies and number of LLETZs observed over three rounds of cytology screening and estimated over two rounds of HPV-screening with cytology triage."
ANSWER: We fully agree with the reviewer. On this background we had also expected to be permitted to undertake the study as a randomized controlled trial where the routine 3-yearly cytology was compared with 6-yearly HPV-testing. The ethical committee was, however, concerned about the safety of a 6-yearly screening, and would not permit a randomized controlled trial without informed consent, which could for logistic reasons not be collected. We have added the following sentence under Objectives: "In this way the screening programme could take into account that the optimal balance between screening-related harms and gains differs between HPV-vaccinated women and previous birth cohorts."
ANSWER: We acknowledge that the study design is a compromise between the optimal design and the design allowed by the Danish Ethical Committee. A cohort study within the existing screening programme would not allow us to calculate what we would have achieved if HPV-testing has substituted cytology as HPV-testing is not performed routinely.
A minor point: l196. If non-inferiority is disproved, analysis for superiority will be carried out.. Disproved => proved. cumulative risk of CIN3+ in baseline screen negative women after an estimated six year 172 interval of HPV-screening compared with two three year intervals of cytology-screening.
ANSWER: This has been changed accordingly. Thank you for pointing out the mistake. Firstly this is not an intervention study (I suppose this is why the ethics committee said it was a 'methods study'). The only intervention is screening as currently practiced and as such it does not differ between the study arms. Therefore it is unclear why randomisation is necessary. The authors state that the intervention is the HPV test performed in addition to cytology in the HPV arm (page 12). But, as can be seen in the flow diagram of the study arms, the HPV test does not influence management in any way i.e. being HPV positive is not used as a marker of elevated risk influencing subsequent follow up or management. Therefore this is not HPV screening and will not provide information about whether such screening is safe or effective in HPV vaccinated women. The most it could do is possibly provide information about whether cytologists detect cytological abnormalities better when they know that the woman is HPV positive given HPV status is unblinded.
ANSWER: You are quite right, this is not an intervention study, it is a method study mimicking the intervention study originally planned but not approved by the Ethical Committee. The decision from the Ethical Committee not to allow randomization of screening test came at a very late stage, where the organization and resource allocation were already in place. We could not double the number of needed HPV-tests, neither could we exclude laboratories. Therefore, we kept randomization of the supplementary HPV-testing. Randomisation will furthermore allow for check on whether the fact that the HPV-status is sometime known before the cytology is read, will have affected the results. The term "method study" is used in Denmark for studies not requiring informed consent. We have added the following sentence under Study design: "… the Danish Ethical Committee required informed consent for permission to randomize screening schedule. Collection of informed consent …"; "… the HPV-test does not affect the clinical management of the woman."; the following sentences under Intervention: "There is no real intervention in this study as it is a method study and the result of the HPV-test does not affect the clinical management of the woman. However, in the intervention arm a HPV-test is performed in addition to routine cytology screening."; and the following sentence to the Discussion: "As there is no real intervention, randomization would not have been needed. However, the decision from the Ethical Committee not to allow randomization of the screening test without informed consent came at a late stage, where the organization and resource allocation were already in place. At that time, we could not double the number of needed HPV-tests neither could we exclude participating laboratories. Therefore, we kept randomization of the supplementary HPV-test. The randomization will furthermore allow for check of a possible difference in the cytology reading between the HPV and the cytology arms. All…"
ANSWER: Thank you for the very valid comment. The baseline data from the study will provide information on HPV-prevalence in an HPV-vaccinated birth cohort. We agree that the design and the primary outcome were not adequately described. We have added the following information to the Study Design: "…a positive HPV-test and normal cells at baseline is re-tested for both HPV and cytology" and the following footnote to Table 1 : "***Women with positive HPV-test and normal cytology at baseline are re-tested after 3 years for both HPV and cytology". We have furthermore changed the text concerning the primary outcome, see Answer to Reviewer 1, point 3.
ANSWER: Again, thank you for the very valid comment. We apologize for not having explained the study design well enough. We have added the following sentences to the Data analysis plan: "The expected outcome of primary HPV-screening with cytology triage will be estimated by including CIN3+ lesions found over the 7 years of follow-up. For the envisioned primary HPV-screening with cytology triage, we will include CIN3+ lesions in women HPV-positive/cytology abnormal at baseline; HPVpositive/cytology normal at baseline, but HPV-positive/cytology abnormal at re-testing after 3 years; or HPV-positive/cytology abnormal at re-screening after 6 year. For the routine cytology screening, we will include CIN3+ lesions in women cytology abnormal at either the baseline screen; at second screen after 3 years, or at third screen after 6 years."
VERSION 2 -REVIEW

REVIEWER
Marion Saville VCS Ltd
REVIEW RETURNED
24-Feb-2018
GENERAL COMMENTS
The authors have addressed the comments raised in the initial review and the manuscript now better reflects the compromise that the investigators have had to made given the Ethics committee determination and the lack of feasibility to get individual consent.
Further refinement of the manuscript should be undertaken to ensure that the study is not interpreted as an RCT, paying particular attention to the title, the "Strengths and limitations of this study " box.
REVIEWER
J. Berkhof VU University Medical Center Amsterdam REVIEW RETURNED
27-Feb-2018
GENERAL COMMENTS
The manuscript has improved considerably, but two minor issues remain.
1. In the limitations it is mentioned that cytology analysis unblinded to HPV-result. Why is this a limitation? I would consider it a limitation when cytology analysis is blinded to the HPV result, because in primary HPV screening, cytology reading will be done with knowledge of the HPV status.
2. The authors seem too modest claiming that their study does not contain a real intervention. Do the authors mean that when a woman from the intervention arm has a positive HPV result and normal cytology and also has a positive HPV test and normal cytology after three years, she will not be referred for further examination but be re-invited 6 years after baseline? Such a strategy is only acceptable when HPV results are blinded to the participating women but they are not, it seems.
There is no real intervention in this study as it is a method study and the result of 222 the HPV-test does 223 not affect the clinical management of the woman. Please leave your comments for the authors below The authors have addressed the comments raised in the initial review and the manuscript now better reflects the compromise that the investigators have had to made given the Ethics committee determination and the lack of feasibility to get individual consent. Further refinement of the manuscript should be undertaken to ensure that the study is not interpreted as an RCT, paying particular attention to the title, the "Strengths and limitations of this study" box.
VERSION 2 -AUTHOR RESPONSE
ANSWER: We have changed the box on Strengths and limitations of this study, so it now reads:
Strengths:
• Embedded in the existing cervical screening program • Cross-regional study including large number of women Limitations:
• Six year screening interval in HPV-arm estimated based on observed data
We also removed 'randomized' from the title which now reads: Protocol of a Danish method study on cervical screening in women offered HPV-vaccination as girls (Trial23) Furthermore, some additional changes have been made in the first section of 'methods and analysis'; we removed 'randomized' in l. 98, introduced a new sentence in l. 108 and altered the sequence of some other sentences. The first section now reads: Trial23 is a method study embedded in the Danish cervical screening program.
Originally, the intention was to compare the present screening method (cytology) to primary HPVtesting with cytology triage with different time intervals. However, the Danish Ethical Committee required informed consent for permission to randomize screening scheme. Collection of informed consent was not feasible due to the large number of participants and decentralized sampling procedure. For this reason, the trial is undertaken as a method study as defined by the Danish Ethical Committees. However, although the design has changed, the objective of the trial is unchanged, and the comparison between the two envisioned schemes will be calculated from the collected data. We therefore operate with the terms "HPV" and "present program arm".
In the method study, the HPV-test is made as a co-test on the cytology sample material without affecting the screening program. The HPV-test does not affect the clinical management of the woman.
